溃疡性结肠炎癌变的中西医防治策略

沈洪; 朱磊; 邢敬

doi:10.3969/j.issn.1671-038X.2023.03.01

溃疡性结肠炎癌变的中西医防治策略

- 南京中医药大学附属医院消化科(南京, 210029)
基金项目:
国家重点研发计划中医药现代化研究专项(No：2017YEC1700104)

详细信息

作者简介:
沈洪，医学博士，教授，二级主任中医师，博士研究生指导老师，博士后合作导师。享受国务院政府特殊津贴专家，首批岐黄学者和全国优秀中医临床人才，全国老中医药专家学术经验继承指导老师，江苏省名中医，江苏省医学领军人才和江苏省中医药领军人才。现任南京中医药大学附属医院(江苏省中医院)消化病研究所所长，江苏省中医消化临床医学研究中心主任，江苏省医学创新中心主任。兼任中国医疗保健国际交流促进会中西医结合脾胃病学分会主任委员、中华中医药学会脾胃病分会副主任委员、世界中医药学会联合会消化病专业委员会副会长、中国民族医药学会脾胃病分会副会长、中国医药教育协会炎症性肠病专业委员会副主任委员、中国中西医结合学会消化系统疾病专业委员会常委、江苏省中医药学会脾胃病专业委员会主任委员、江苏省医学会消化病学分会炎症性肠病学组组长等。《中国中西医结合消化杂志》和《南京中医药大学学报》副主编，《中医杂志》和《北京中医药》等杂志编委。主持国家级课题7项，省部级课题6项。获省部级科学技术进步二等奖5项、中药新药证书1项、发明专利3项和软件著作权3项。主编《溃疡性结肠炎—中西医的过去、现在与未来》等专著10部，副主编专著7部。发表SCI论文22篇，核心期刊论文280余篇

通讯作者: 沈洪, E-mail: shenhong999@163.com

中图分类号: R574.62

收稿日期: 2023-01-28

刊出日期: 2023-03-15

Strategies and methods of Traditional Chinese Medicine in the prevention and treatment of ulcerative colitis associated colorectal cancer

- Department of Gastroenterology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China

More Information

Corresponding author: SHEN Hong,E-mail:shenhong999@163.com

Received Date: 28 January 2023

Publish Date: 15 March 2023

摘要

摘要: 溃疡性结肠炎是结直肠癌发生的重要危险因素，如何有效控制炎症、降低溃疡性结肠炎癌变发生率是临床重要问题。中医药多成分、多环节和多靶点的作用特点，在控制炎症、预防癌变、已变防复方面具有重要意义。本文对溃疡性结肠炎相关结直肠癌的发病机制、监测预防及中医药防治癌变的研究进展进行总结，重在探讨中医药防治溃疡性结肠炎癌变的策略，以期为临床提供参考。
- 中医药 /
- 溃疡性结肠炎 /
- 溃疡性结肠炎相关结直肠癌 /
- 治疗策略
Abstract: Ulcerative colitis is an important risk factor for colorectal cancer. How to control the inflammation of ulcerative colitis effectively and reduce the incidence of ulcerative colitis canceration is an important research contents of ulcerative colitis. The characteristics of multi-component, multi-link and multi-target of Traditional Chinese Medicine(TCM) play an important role in controlling inflammation, preventing canceration and preventing recurrence after operation. This article summarizes the pathogenesis, monitoring and prevention of colorectal cancer associated with colitis, and the research progress in the prevention and treatment of canceration with TCM, focusing on the discussion of strategies and methods of TCM in the prevention and treatment of ulcerative colitis associated colorectal cancer, in order to better guide clinical practice.
- Traditional Chinese Medicine /
- ulcerative colitis /
- ulcerative colitis-associated colorectal cancer /
- treatment strategy

HTML全文

参考文献(41)

[1]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J National Cancer Center, 2022, 2(1): 1-9. doi: 10.1016/j.jncc.2022.02.002
[2]	Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480. doi: 10.1016/S0140-6736(19)32319-0
[3]	Linson EA, Hanauer SB. Epidemiology of colorectal cancer in inflammatory bowel disease-the evolving landscape[J]. Curr Gastroenterol Rep, 2021, 23(9): 16. doi: 10.1007/s11894-021-00816-3
[4]	Bopanna S, Ananthakrishnan AN, Kedia S, et al. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2017, 2(4): 269-276. doi: 10.1016/S2468-1253(17)30004-3
[5]	Baker AM, Cross W, Curtius K, et al. Evolutionary history of human colitis-associated colorectal cancer[J]. Gut, 2019, 68(6): 985-995. doi: 10.1136/gutjnl-2018-316191
[6]	Arai N, Kudo T, Tokita K, et al. Expression of oncogenic molecules in pediatric ulcerative colitis[J]. Digestion, 2022, 103(2): 150-158. doi: 10.1159/000519559
[7]	Thorsteinsdottir S, Gudjonsson T, Nielsen OH, et al. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(7): 395-404. doi: 10.1038/nrgastro.2011.96
[8]	Xue M, Shi LH, Wang WJ, et al. An overview of molecular profiles in ulcerative colitis-related cancer[J]. Inflamm Bowel Dis, 2018, 24(9): 1883-1894. doi: 10.1093/ibd/izy221
[9]	Grillo TG, Quaglio AEV, Beraldo RF, et al. MicroRNA expression in inflammatory bowel disease-associated colorectal cancer[J]. World J Gastrointest Oncol, 2021, 13(9): 995-1016. doi: 10.4251/wjgo.v13.i9.995
[10]	Guo J, Liao MF, Wang J. TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155[J]. Cell Commun Signal, 2021, 19(1): 90. doi: 10.1186/s12964-021-00771-6
[11]	Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer[J]. Nat Rev Immunol, 2021, 21(10): 653-667. doi: 10.1038/s41577-021-00534-x
[12]	Pagano E, Elias JE, Schneditz G, et al. Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment[J]. Gut, 2022, 71(3): 509-520. doi: 10.1136/gutjnl-2020-323363
[13]	Liang LF, Lin RX, Xie Y, et al. The role of cyclophilins in inflammatory bowel disease and colorectal cancer[J]. Int J Biol Sci, 2021, 17(10): 2548-2560. doi: 10.7150/ijbs.58671
[14]	Nakatsu G, Li XC, Zhou HK, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis[J]. Nat Commun, 2015, 6: 8727. doi: 10.1038/ncomms9727
[15]	Janney A, Powrie F, Mann EH. Host-microbiota maladaptation in colorectal cancer[J]. Nature, 2020, 585(7826): 509-517. doi: 10.1038/s41586-020-2729-3
[16]	Wang Z, Guo K, Liu Y, et al. Dynamic impact of virome on colitis and colorectal cancer: immunity, inflammation, prevention and treatment[J]. Semin Cancer Biol, 2022, 86: 943-954. doi: 10.1016/j.semcancer.2021.10.004
[17]	Li WQ, Zhao TT, Wu DC, et al. Colorectal cancer in ulcerative colitis: mechanisms, surveillance and chemoprevention[J]. Curr Oncol, 2022, 29(9): 6091-6114. doi: 10.3390/curroncol29090479
[18]	Yalchin M, Baker AM, Graham TA, et al. Predicting colorectal cancer occurrence in IBD[J]. Cancers, 2021, 13(12): 2908. doi: 10.3390/cancers13122908
[19]	Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review[J]. Gastroenterology, 2021, 161(3): 1043-1051. e4. doi: 10.1053/j.gastro.2021.05.063
[20]	Choi CHR, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview[J]. Am J Gastroenterol, 2015, 110(7): 1022-1034. doi: 10.1038/ajg.2015.65
[21]	Curtius K, Kabir M, Al Bakir I, et al. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool[J]. Gut, 2022, 71(4): 705-715. doi: 10.1136/gutjnl-2020-323546
[22]	Ananthakrishnan AN, Cheng SC, Cai T, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases[J]. Clin Gastroenterol Hepatol, 2014, 12(8): 1342-1348. e1. doi: 10.1016/j.cgh.2013.12.030
[23]	Koutroubakis IE, Regueiro M, Schoen RE, et al. Multiyear patterns of serum inflammatory biomarkers and risk of colorectal neoplasia in patients with ulcerative colitis[J]. Inflamm Bowel Dis, 2016, 22(1): 100-105. doi: 10.1097/MIB.0000000000000587
[24]	Rasic I, Radovic S, Aksamija G. Relationship between chronic inflammation and the stage and histopathological size of colorectal carcinoma[J]. Med Arch, 2016, 70(2): 104-107. doi: 10.5455/medarh.2016.70.104-107
[25]	Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis[J]. World J Gastroenterol, 2014, 20(29): 9872-9881. doi: 10.3748/wjg.v20.i29.9872
[26]	Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine[J]. Aliment Pharmacol Ther, 2010, 31(2): 202-209.
[27]	Charkaoui M, Hajage D, Tubach F, et al. Impact of anti-tumour necrosis factor agents on the risk of colorectal cancer in patients with ulcerative colitis: nationwide French cohort study[J]. J Crohns Colitis, 2022, 16(6): 893-899. doi: 10.1093/ecco-jcc/jjab184
[28]	Karstensen JG, Ebigbo A, Desalegn H, et al. Colorectal polypectomy and endoscopic mucosal resection: European society of gastrointestinal endoscopy cascade guideline[J]. Endosc Int Open, 2022, 10(11): E1427-E1433. doi: 10.1055/a-1964-7965
[29]	齐雪阳, 张勤生, 张春燕. 芍药汤加减保留灌肠联合美沙拉嗪肠溶片治疗大肠湿热证溃疡性结肠炎[J]. 中国实验方剂学杂志, 2016, 22(19): 149-153. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201619031.htm
[30]	林小常. 芍药汤调控炎症因子改善EMT防治结肠炎相关癌的机制研究[D]. 广州: 南方医科大学, 2015.
[31]	Wang XY, Saud SM, Zhang XW, et al. Protective effect of Shaoyao Decoction against colorectal cancer via the Keap1-Nrf2-ARE signaling pathway[J]. J Ethnopharmacol, 2019, 241: 111981. doi: 10.1016/j.jep.2019.111981
[32]	Sui H, Zhang L, Gu KJ, et al. YYFZBJS ameliorates colorectal cancer progression in Apc^Min/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation[J]. Cell Commun Signal, 2020, 18(1): 113. doi: 10.1186/s12964-020-00596-9
[33]	王军文, 李克亚, 陆文洪, 等. 乌梅丸联合美沙拉嗪对寒热错杂型溃疡性结肠炎患者的临床疗效[J]. 中成药, 2022, 44(11): 3493-3497. doi: 10.3969/j.issn.1001-1528.2022.11.015
[34]	Deng S, Tang Q, Duan X, et al. Uncovering the Anticancer Mechanism of Compound Sophorae Decoction against Ulcerative Colitis-Related Colorectal Cancer in Mice[J]. Evid Based Complement Alternat Med, 2019, 2019: 8128170.
[35]	李方, 郑楠, 赵亚娇, 等. 复方血竭制剂对小鼠溃疡性结肠炎相关结直肠癌的疗效及可能机制[J]. 安徽医科大学学报, 2017, 52(1): 13-17. https://www.cnki.com.cn/Article/CJFDTOTAL-YIKE201701003.htm
[36]	江东, 徐长亮, 沈卫星, 等. 参白解毒方对溃疡性结肠炎肠黏膜上皮细胞保护作用机制研究[J]. 陕西中医, 2022, 43(1): 23-27. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZY202201005.htm
[37]	孙姮, 闫珺, 李雨, 等. 基于分子对接探讨还涎方抑制溃疡性结肠炎癌前病变的机制[J]. 中华中医药杂志, 2022, 37(5): 2826-2830. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202205075.htm
[38]	Li H, Lai ZJ, Yang H, et al. Hedyotis diffusa Willd. inhibits VEGF-C-mediated lymphangiogenesis in colorectal cancer via multiple signaling pathways[J]. Oncol Rep, 2019, 42(3): 1225-1236.
[39]	Zu MH, Xie DC, Canup BSB, et al. Green nanotherapeutics from tea leaves for orally targeted prevention and alleviation of colon diseases[J]. Biomaterials, 2021, 279: 121178. doi: 10.1016/j.biomaterials.2021.121178
[40]	Chen P, Li XJ, Zhang RN, et al. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation[J]. Theranostics, 2020, 10(11): 5107-5119. doi: 10.7150/thno.44705
[41]	Tao YL, Zhan SB, Wang YB, et al. Baicalin, the major component of traditional Chinese medicine Scutellaria baicalensis induces colon cancer cell apoptosis through inhibition of oncomiRNAs[J]. Sci Rep, 2018, 8(1): 14477. doi: 10.1038/s41598-018-32734-2